Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan + Chlorthalidone vs Benicar HCT in hypertension
NCT02483936Phase 3Withdrawn
- Sponsor
- EMS
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of chlorthalidone in hypertension (HTN) (4 arms), sponsored by EMS. Primary endpoint: Reduction of systolic blood pressure at 60 days. Status: withdrawn.
02
Drugs
chlorthalidone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02483936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483936.